NEW YORK (GenomeWeb News) – Illumina and Genpathway have partnered to offer scientists a solution for studying transcription factor binding and gene regulation in drug development research, Illumina said today.
Under the partnership, Genpathway will prepare samples using its FactorPath ChIP assays and will conduct data analysis using its software. The sequencing will be handled by Illumina’s Sequencing Services, which will employ the firm’s high-throughput Genome Analyzer, the company said.
The combined services the companies plan to offer include cell or tissue processing, antibody selection and qualification, and ChIP DNA amplification, Illumina said.
Because ChIP sequencing is “a notoriously time-consuming and difficult procedure,” Genpathway CSO Mary Harper said in a statement, the partnership will allow the companies to offer scientists “a faster path to discovery.”